TriSalus Life Sciences Inc. announced the appointment of Liselotte Hyveled to its board of directors. The Board appointed Liselotte Hyveled as a Class I director of the Company, with a term of office expiring at the 2024 annual meeting of stockholders. There are no arrangements or understandings between Ms. Hyveled and any other person pursuant to which she was selected as a director.

Ms. Hyveled brings over two decades of experience stimulating scientific innovation and advancing pharmaceutical pipelines through research and development excellence. Ms. Hyveled is a seasoned executive with over two decades of successfully implementing innovative solutions for challenging chronic diseases within a rapidly changing, highly competitive R&D environment. Currently serving as the Chief Patient Officer at Novo Nordisk, she is responsible for ensuring the integration of patient needs and perspectives into the company's decision-making processes and operations, from inception to commercialization.

Ms. Hyveled's tenure at Novo Nordisk has been marked by numerous leadership positions and contributions, reflecting her commitment to R&D excellence, breakthrough innovation and advancing patient-centric solutions. She has initiated several social responsibility initiatives at Novo Nordisk with a focus on neurodiversity, disabilities and generational intelligence. Ms. Hyveled holds a Master of Pharmacy Science from Copenhagen University and a Master of Medical Business Strategies from Copenhagen Business School.

Ms. Hyveled will also serve as a member of the Nominating and Corporate Governance Committee of the Board (the Nominating Committee) and the Science and Technology Committee of the Board (the Science and Technology Committee).